HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An siRNA Screen Identifies the U2 snRNP Spliceosome as a Host Restriction Factor for Recombinant Adeno-associated Viruses.

Abstract
Adeno-associated viruses (AAV) have evolved to exploit the dynamic reorganization of host cell machinery during co-infection by adenoviruses and other helper viruses. In the absence of helper viruses, host factors such as the proteasome and DNA damage response machinery have been shown to effectively inhibit AAV transduction by restricting processes ranging from nuclear entry to second-strand DNA synthesis. To identify host factors that might affect other key steps in AAV infection, we screened an siRNA library that revealed several candidate genes including the PHD finger-like domain protein 5A (PHF5A), a U2 snRNP-associated protein. Disruption of PHF5A expression selectively enhanced transgene expression from AAV by increasing transcript levels and appears to influence a step after second-strand synthesis in a serotype and cell type-independent manner. Genetic disruption of U2 snRNP and associated proteins, such as SF3B1 and U2AF1, also increased expression from AAV vector, suggesting the critical role of U2 snRNP spliceosome complex in this host-mediated restriction. Notably, adenoviral co-infection and U2 snRNP inhibition appeared to target a common pathway in increasing expression from AAV vectors. Moreover, pharmacological inhibition of U2 snRNP by meayamycin B, a potent SF3B1 inhibitor, substantially enhanced AAV vector transduction of clinically relevant cell types. Further analysis suggested that U2 snRNP proteins suppress AAV vector transgene expression through direct recognition of intact AAV capsids. In summary, we identify U2 snRNP and associated splicing factors, which are known to be affected during adenoviral infection, as novel host restriction factors that effectively limit AAV transgene expression. Concurrently, we postulate that pharmacological/genetic manipulation of components of the spliceosomal machinery might enable more effective gene transfer modalities with recombinant AAV vectors.
AuthorsClaire A Schreiber, Toshie Sakuma, Yoshihiro Izumiya, Sara J Holditch, Raymond D Hickey, Robert K Bressin, Upamanyu Basu, Kazunori Koide, Aravind Asokan, Yasuhiro Ikeda
JournalPLoS pathogens (PLoS Pathog) Vol. 11 Issue 8 Pg. e1005082 (Aug 2015) ISSN: 1553-7374 [Electronic] United States
PMID26244496 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Carrier Proteins
  • PHF5A protein, human
  • RNA, Small Interfering
  • RNA-Binding Proteins
  • Ribonucleoprotein, U2 Small Nuclear
  • Trans-Activators
Topics
  • Carrier Proteins (metabolism)
  • Cell Line
  • Dependovirus (genetics, pathogenicity)
  • Genetic Vectors
  • Genomic Library
  • Host-Parasite Interactions (physiology)
  • Humans
  • Immunoblotting
  • Immunoprecipitation
  • Microscopy, Confocal
  • RNA, Small Interfering
  • RNA-Binding Proteins
  • Reverse Transcriptase Polymerase Chain Reaction
  • Ribonucleoprotein, U2 Small Nuclear (metabolism)
  • Spliceosomes (metabolism)
  • Trans-Activators
  • Transduction, Genetic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: